In JAMS arbitration, CRA was retained by the Claimant regarding a dispute involving the breach of fiduciary duty by former employees of a clinical stage therapeutic company. CRA estimated the Claimant’s cash flows using contemporaneous Claimant’s financial data, colorectal cancer incidence rates and treatment prices, relevant clinical trial and generic market entry studies, and potentially comparable companies financials. Such information, along with qualitative information, was considered to estimate the Claimant’s risk-adjusted net present value. Claimant presented our valuation methodology and work product in its mediation, which CRA attended.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...